Related and Nonrelated Parties [Axis]
Nonrelated Party [Member]
Related Party [Member]
Class of Stock [Axis]
Series C-1 Preferred Stock [Member]
Series C-2 Preferred Stock [Member]
Product and Service [Axis]
Clinic Revenue [Member]
Product [Member]
Equity Components [Axis]
Common Stock [Member]
Preferred Stock [Member]
Series A Preferred Stock [Member]
Series B Preferred Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Treasury Stock, Preferred [Member]
Statistical Measurement [Axis]
Minimum [Member]
Maximum [Member]
Measurement Input Type [Axis]
Measurement Input Calibrated Discount Rate [Member]
Fair Value Hierarchy and NAV [Axis]
Fair Value, Inputs, Level 1 [Member]
Fair Value, Inputs, Level 2 [Member]
Fair Value, Inputs, Level 3 [Member]
Measurement Input, Option Volatility [Member]
Measurement Input, Expected Term [Member]
Measurement Input, Expected Dividend Rate [Member]
Measurement Input, Risk Free Interest Rate [Member]
Antidilutive Securities [Axis]
Share-Based Payment Arrangement, Option [Member]
Convertible Notes and Interest [Member]
Convertible Preferred Stock [Member]
Warrant [Member]
Revision of Prior Period [Axis]
Previously Reported [Member]
Revision of Prior Period, Reclassification, Adjustment [Member]
Redeemable Preferred Stock [Member]
Business Combination [Axis]
Legacy Naya Merger [Member]
Common Class A [Member]
Common Class B [Member]
Series C-1 Convertible Preferred Stock [Member]
Legal Entity [Axis]
Five Narrow Lane LP [Member]
Series C-2 Convertible Preferred Stock [Member]
NAYA Therapeutics Inc [Member]
Asset Acquisition [Axis]
NAYA Therapeutics [Member]
Finite-Lived Intangible Assets by Major Class [Axis]
Trade Names [Member]
In Process Research and Development [Member]
Bloom INVO LLC [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Bloom Agreement [Member]
Consolidated Entities [Axis]
Georgia JV [Member]
Alabama JV [Member]
Debt Instrument [Axis]
Alabama JV Note Receivable [Member]
Investment, Name [Axis]
HRCFG INVO, LLC [Member]
Variable Interest Entity, Primary Beneficiary [Member]
Variable Interest Entity, Not Primary Beneficiary [Member]
Long-Lived Tangible Asset [Axis]
Manufacturing Equipment [Member]
Medical Equipment [Member]
Office Equipment [Member]
Leasehold Improvements [Member]
Asset Class [Axis]
Fertility Clinic Services [Member]
Therapeutics [Member]
Goodwill [Member]
Wisconsin Fertility Institute Acquisition [Member]
Noncompete Agreements [Member]
Assembled Workforce [Member]
Related Party Demand Notes [Member]
Related Party Convertible Notes [Member]
Convertible Notes Payable [Member]
Convertible Note Payable One [Member]
Cash Advance Agreement [Member]
Note Payable [Member]
Convertible Debenture Payable [Member]
Notes Payable One [Member]
Other Debt [Member]
Other [Member]
JAG Multi Investments LLC [Member]
JAG Amendment [Member]
JAG August Letter [Member]
Title and Position [Axis]
Chief Executive Officer [Member]
Chief Financial Officer [Member]
Sept 24 Cash Advance Agreement [Member]
Cedar [Member]
Revenue Loan and Security Agreement [Member]
Future Receipts Agreement [Member]
FirstFire Purchase Agreement [Member]
Class of Warrant or Right [Axis]
First Warrant [Member]
Second Warrant [Member]
Carter Terry and Company Inc [Member]
Financial Instrument [Axis]
7% Secured Convertible Debenture [Member]
Derivative Instrument [Axis]
May 2025 Amended And Restated Debenture [Member]
AIR Exercise and Reload Agreement [Member]
August 2025 Amended and Restated Debenture [Member]
Original Debenture [Member]
First Amended and Restated Debenture [Member]
Second Amended and Restate Debenture [Member]
Convertible Debenture [Member]
Board of Directors [Member]
Nonconsolidated Investees, Other [Member]
Securities Purchase Agreement [Member]
Pre-Funded Warrants [Member]
Common Warrants [Member]
Sale of Stock [Axis]
December 2025 Private Placement [Member]
First Fire Warrant [Member]
Plan Name [Axis]
2019 Stock Incentive Plan [Member]
Consultants [Member]
Stock Incentive Plan [Member]
Award Type [Axis]
Share-Based Payment Arrangement [Member]
Restricted Stock Units (RSUs) [Member]
Unit Purchase Options [Member]
Prefunded Warrant [Member]
Inducement Letter Agreement [Member]
New Warrant [Member]
Existing Warrants [Member]
December 2025 Warrants [Member]
Customer [Axis]
No Customers [Member]
Concentration Risk Benchmark [Axis]
Revenue Benchmark [Member]
Concentration Risk Type [Axis]
Customer Concentration Risk [Member]
Accounts Receivable [Member]
Segments [Axis]
Consolidation Items [Axis]
Operating Segments [Member]
Revenue From External Customers [Member]
INVOcell Device [Member]
Inter Segment Revenue [Member]
Indefinite-Lived Intangible Assets [Axis]
Income Tax Jurisdiction [Axis]
Foreign Tax Jurisdiction [Member]
Vesting [Axis]
Second Installment [Member]
Scenario [Axis]
Forecast [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
Warrant Inducement Agreement [Member]
Family Beginnings P C [Member]
Series D Preferred Stock [Member]
J A G Notes [Member]
Cover [Abstract]
Document Type
Amendment Flag
Amendment Description
Document Registration Statement
Document Annual Report
Document Quarterly Report
Document Transition Report
Document Shell Company Report
Document Shell Company Event Date
Document Period Start Date
Document Period End Date
Document Fiscal Period Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Entity File Number
Entity Registrant Name
Entity Central Index Key
Entity Primary SIC Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Three
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Country
Entity Address, Postal Zip Code
Country Region
City Area Code
Local Phone Number
Extension
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
No Trading Symbol Flag
Trading Symbol
Security Exchange Name
Title of 12(g) Security
Security Reporting Obligation
Annual Information Form
Audited Annual Financial Statements
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Elected Not To Use the Extended Transition Period
Document Accounting Standard
Other Reporting Standard Item Number
Entity Shell Company
Entity Public Float
Entity Bankruptcy Proceedings, Reporting Current
Entity Common Stock, Shares Outstanding
Documents Incorporated by Reference [Text Block]
ICFR Auditor Attestation Flag
Document Financial Statement Error Correction [Flag]
Document Financial Statement Restatement Recovery Analysis [Flag]
Entity Listing, Par Value Per Share
Auditor Firm ID
Auditor Opinion [Text Block]
Auditor Name
Auditor Location
Statement [Table]
Statement [Line Items]
ASSETS
Current assets
Cash
Accounts receivable, net of allowances of $69,641 and $61,773 as of December 31, 2025 and 2024, respectively
Inventory
Prepaid expenses and other current assets
Current assets held for disposition
Total current assets
Property and equipment, net
Lease right of use
Intangible assets, net
Goodwill
Investment in NAYA Therapeutics
Note receivable
Noncurrent assets held for disposition
Total assets
LIABILITIES, MEZZANINE EQUITY, AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable and accrued liabilities
Accrued compensation
Notes payable , net
Deferred revenue
Lease liability, current portion
Additional payments for acquisition, current portion
Derivative liability
Other current liabilities
Current liabilities held for disposition
Total current liabilities
Lease liability, net of current portion
Liability for excess losses of equity method investee
Notes payable – net of current portion
Deferred tax liability
Additional payments for acquisition, net of current portion
Total liabilities
Mezzanine equity
Series C-2 Preferred Stock (mezzanine) $1,000.00 par value; 20,000 shares authorized; 3,004 and 8,576 issued and outstanding as of December 31, 2025 and 2024, respectively.
Stockholders’ equity
Preferred stock value
Common Stock, $.0001 par value; 6,250,000 shares authorized; 477,366 and 3,111 issued and outstanding as of December 31, 2025 and 2024, respectively
Additional paid-in capital
Accumulated deficit
Total stockholders’ equity
Total liabilities, mezzanine, and stockholders’ equity
Accounts receivable, net of allowances
Temporary stock, par value
Temporary stock, shares authorized
Temporary stock, shares issued
Temporary stock, shares outstanding
Preferred stock, par value
Preferred stock, shares authorized
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Revenue:
Total revenue
Operating expenses:
Cost of services
Cost of goods sold
Selling, general and administrative expenses
Research and development expenses
Impairment of intangible assets
Loss on disposal of fixed assets
Depreciation and amortization
Total operating expenses
Loss from operations
Other income (expense):
Gain from equity method joint ventures
Gain on changes in fair value
Gain on lease termination
Loss from debt extinguishment
Loss on issuance of warrants
Gain on settlement of liability (Note 18)
Interest expense
Total other income (expenses)
Net loss before income taxes
Provision (benefit) for income taxes
Net loss from continuing operations
Loss on disposal of NTI (Note 4)
Loss on discontinued operations of NTI (Note 4)
Net loss
Preferred stock dividends and deemed dividends
Net loss attributable to common shareholders
Net loss from continuing operations per common share:
Basic
Diluted
Net loss from discontinued operations per common share:
Basic
Diluted
Net loss per common share:
Basic
Diluted
Weighted average number of common shares outstanding:
Basic
Diluted
Balance
Balances, shares
Mezzanine equity, shares
Mezzanine equity, value
Preferred stock redemption, value
Common stock issued to service providers
Common stock issued to service providers, shares
Stock issued for cash
Stock issued for cash, shares
Preferred stock issued
Preferred stock issued, shares
Stock options issued to directors and employees
Warrants issued with notes payable
Convertible note modification/extinguishment
Debt conversion
Debt conversion, shares
Warrants issued
Warrant exercise
Warrant exercise, shares
Consideration for NAYA Therapeutics, value
Consideration for NAYA Therapeutics, shares
NAYA debt conversion
Deemed dividend
Returned shares
Returned shares, shares
Net loss attributable to INVO Fertility, Inc.
Reclassification of Series C-2 Preferred stock from mezzanine equity, value
Reclassification of Series C-2 Preferred stock from mezzanine equity, shares
Preferred stock redemption, shares
Proceeds from the sale of common stock, net of fees and expenses
Proceeds from the sale of common stock, net of fees and expenses, shares
Warrant exercise - cashless
Warrant exercise - cashless, shares
Warrant exercise - pre-funded
Warrant exercise - prefunded, shares
C-1 to C-2 exchange
C-1 to C-2 exchange, shares
Divesture of NAYA
Divesture of NAYA, shares
Proceeds from the sale of preferred stock
Proceeds from the sale of preferred stock, shares
Dividends on preferred stock
Dividends on preferred stock, shares
C-2 to common stock exchange
C-2 to common stock exchange, shares
Fair value of warrants issued with notes payable
Changes in fair value of derivatives
Rounding for reverse split
Rounding for reverse split, shares
Balance
Balances, shares
Mezzanine equity, shares
Mezzanine equity, value
Mezzanine equity, value
Statement of Cash Flows [Abstract]
Cash flows from operating activities:
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash stock compensation issued for services
Non-cash stock compensation issued to directors and/or employees
Fair value of stock options issued to employees
Non-cash compensation for services
Amortization of discount on notes payable
Impairment loss
Reserve on other assets
(Gain) Loss from equity method investment
Loss from debt extinguishment
Loss on disposal of fixed assets
Gain on lease termination
Loss on disposition
Loss on issuance of warrants
Gain on changes in fair value
Gain on settlement
Depreciation and amortization
Changes in assets and liabilities:
Accounts receivable
Inventory
Prepaid expenses and other current assets
Equity investments
Accounts payable and accrued expenses
Accrued compensation
Deferred revenue
Other current liabilities
Leasehold liability
Accrued interest
Deferred tax liabilities
Net cash used in operating activities
Cash used in investing activities:
Payments to acquire property, plant, and equipment
Proceeds from sale of fixed assets
Cash acquired in acquisition
Divesture of NTI
Payment for acquisitions
Net cash used in investing activities
Cash from financing activities:
Proceeds from notes payable
Proceeds from the sale of common stock, net of offering costs
Proceeds from the sale of preferred stock
Proceeds from warrant exercise
Preferred stock redemption
Principal payments on notes payable
Net cash provided by financing activities
Increase in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental disclosure of cash flow information:
Interest
Taxes
Noncash activities:
Fair value of preferred stock issued for acquisition
Common stock and preferred stock issued upon conversion notes payable and accrued interest
Dividends on preferred stock
Deemed dividend
Fair value of warrants issued with debt
C-2 to common stock exchange
Preferred stock redemption adjustment
Preferred stock exchange
Common stock issued for accounts payable
Pay vs Performance Disclosure [Table]
Executive Category [Axis]
Individual [Axis]
Adjustment to Compensation [Axis]
Measure [Axis]
Pay vs Performance Disclosure, Table
Company Selected Measure Name
Named Executive Officers, Footnote
Peer Group Issuers, Footnote
Changed Peer Group, Footnote
PEO Total Compensation Amount
PEO Actually Paid Compensation Amount
Adjustment To PEO Compensation, Footnote
Non-PEO NEO Average Total Compensation Amount
Non-PEO NEO Average Compensation Actually Paid Amount
Adjustment to Non-PEO NEO Compensation Footnote
Equity Valuation Assumption Difference, Footnote
Compensation Actually Paid vs. Total Shareholder Return
Compensation Actually Paid vs. Net Income
Compensation Actually Paid vs. Company Selected Measure
Total Shareholder Return Vs Peer Group
Compensation Actually Paid vs. Other Measure
Tabular List, Table
Total Shareholder Return Amount
Peer Group Total Shareholder Return Amount
Net Income (Loss)
Company Selected Measure Amount
Other Performance Measure, Amount
Adjustment to Compensation, Amount
PEO Name
Name
Non-GAAP Measure Description
Additional 402(v) Disclosure
Pension Benefits Adjustments, Footnote
Equity Awards Adjustments, Footnote
Erroneously Awarded Compensation Recovery [Table]
Restatement Determination Date [Axis]
Restatement Determination Date
Aggregate Erroneous Compensation Amount
Erroneous Compensation Analysis
Stock Price or TSR Estimation Method
Outstanding Aggregate Erroneous Compensation Amount
Aggregate Erroneous Compensation Not Yet Determined
Name
Forgone Recovery due to Expense of Enforcement, Amount
Forgone Recovery due to Violation of Home Country Law, Amount
Forgone Recovery due to Disqualification of Tax Benefits, Amount
Forgone Recovery, Explanation of Impracticability
Name
Compensation Amount
Restatement does not require Recovery
Awards Close in Time to MNPI Disclosures [Table]
Award Timing MNPI Disclosure
Award Timing Method
Award Timing Predetermined
Award Timing MNPI Considered
Award Timing, How MNPI Considered
MNPI Disclosure Timed for Compensation Value
Awards Close in Time to MNPI Disclosures, Table
Name
Underlying Securities
Exercise Price
Fair Value as of Grant Date
Underlying Security Market Price Change
Insider Trading Arrangements [Line Items]
Material Terms of Trading Arrangement
Name
Title
Rule 10b5-1 Arrangement Adopted
Non-Rule 10b5-1 Arrangement Adopted
Adoption Date
Rule 10b5-1 Arrangement Terminated
Non-Rule 10b5-1 Arrangement Terminated
Termination Date
Expiration Date
Arrangement Duration
Aggregate Available
No insider trading flag
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted
Insider Trading Policies and Procedures Not Adopted
Cybersecurity Risk Management, Strategy, and Governance [Abstract]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]
Cybersecurity Risk Management Processes Integrated [Flag]
Cybersecurity Risk Management Processes Integrated [Text Block]
Cybersecurity Risk Management Third Party Engaged [Flag]
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]
Cybersecurity Risk Board of Directors Oversight [Text Block]
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]
Cybersecurity Risk Role of Management [Text Block]
Cybersecurity Risk Management Positions or Committees Responsible [Flag]
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]
Cybersecurity Risk Management Expertise of Management Responsible [Text Block]
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]
Material Cybersecurity Incident [Abstract]
Material Cybersecurity Incident Nature [Text Block]
Material Cybersecurity Incident Scope [Text Block]
Material Cybersecurity Incident Timing [Text Block]
Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]
Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]
Accounting Policies [Abstract]
Summary of Significant Accounting Policies
Accounting Changes and Error Corrections [Abstract]
Restatements and Revisions
ScheduleOfRestatementAdjustmentOfInterimCTable [Table]
Balances, June 30, 2025
Balance, shares
Mezzanine equity, shares
Mezzanine equity, value
Reclassification of C-1 Preferred Stock
Reclassification of C-1 Preferred Stock, shares
Reclassification of Series C-1 Preferred stock from mezzanine equity, value
Reclassification of Series C-2 Preferred stock
Reclassification of Series C-2 Preferred stock from mezzanine equity, value
C-1 to C-2 exchange from mezzanine equity, value
Divesture of NAYA from mezzanine equity, value
Preferred stock issued
Preferred stock issued, shares
Preferred stock issued from mezzanine equity, value
Net loss
Debt conversion from mezzanine equity, value
Fair value of warrants issued with notes
Balances, September 30, 2025
Balance, shares
Mezzanine equity, shares
Mezzanine equity, value
Debt conversion from mezzanine equity, shares
C-1 to C-2 exchange from mezzanine equity, shares
Divesture of NAYA from mezzanine equity, shares
Preferred stock issued from mezzanine equity, shares
Reclassification of Series C-1 Preferred stock from mezzanine equity, shares
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity
Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]
Business Combinations
Variable Interest Entities
Agreements And Transactions With Vies
Agreements and Transactions with VIE’s
Inventory Disclosure [Abstract]
Inventory
Property, Plant and Equipment [Abstract]
Property and Equipment
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets & Goodwill
Leases
Leases
Debt Disclosure [Abstract]
Notes Payable
Related Party Transactions [Abstract]
Related Party Transactions
Equity [Abstract]
Stockholders’ Equity
Equity-Based Compensation
Unit Purchase Options And Warrants
Unit Purchase Options and Warrants
Segment Reporting [Abstract]
Segment Reporting
Income Tax Disclosure [Abstract]
Income Taxes
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies
Subsequent Events [Abstract]
Subsequent Events
Description of Business
Basis of Presentation
Business Acquisitions
Discontinued Operations
Variable Interest Entities
Equity Method Investments
Use of Estimates
Cash and Cash Equivalents
Accounts Receivable, net
Inventory
Property and Equipment
Long- Lived Assets
Fair Value of Financial Instruments
Derivatives
Income Taxes
Revenue Recognition
Deferred Revenue
Stock Based Compensation
Loss Per Share
Recently Adopted Accounting Pronouncements
Accounting Pronouncements Not Yet Adopted
Schedule of Accounts Receivable
Schedule of Fair Value on Recurring Basis
Schedule of Changes in Fair Value
Schedule of Black-scholes Valuation Model Fair Value of the Warrants
Schedule of Deferred Revenue
Schedule of Earnings Per Share Basic and Diluted
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
Schedule of Effects of Restatement Adjustments
Business Combination [Table]
Business Combination [Line Items]
Schedule of Allocation of Purchase Price
Schedule of Assets and Liabilities Held for Disposal
Schedule of Investments in Unconsolidated Variable Interest Entities
Schedule of Earnings from Investments in Unconsolidated Variable Interest Entities
Schedule of Financial Information of Investments in Unconsolidated Variable Interest Entities
Summary of Transaction with Variable Interest Entities
Summary of Balances with Variable Interest Entities
Schedule of Inventory
Schedule of Estimated Useful Lives of Property and Equipment
Schedule of Property and Equipment
Schedule of Finite-Lived Intangible Assets
Schedule of Carrying Amount of Goodwill
Schedule of Estimated Future Amortization Expense
Schedule of Lease Components
Schedule of Future Minimum Lease Payments
Schedule of Notes Payable
Schedule of Long-term Debt Maturities
Schedule of Stock Options Activity
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions
Schedule of Share Based Payments Arrangements Options Exercised and Options Vested
Schedule of Unit Purchase Option Activity
Schedule of Pre-funded Warrants Activity
Schedule of Company’s Segments Including a Reconciliation to Income Before Taxes
Schedule of Provision for Income Taxes
Schedule of Effective Income Tax Rate Reconciliation
Schedule of Deferred Tax Assets and Liabilities
Balance as of beginning of year
Additions to accounts receivable
Reductions to accounts receivable
Balance as of end of year
Allowance for doubtful accounts
Accounts receivable, net
Platform Operator, Crypto Asset [Table]
Platform Operator, Crypto Asset [Line Items]
Warrant liability
Fair value, note receivable
Fair value, warrant liability
Initial fair value, note receivable
Initial fair value, warrant liability
Change in valuation, note receivable
Change in valuation, warrant liability
Fair value, note receivable
Fair value, warrant liability
Fair value of warrants
Balance as of beginning of year
Additions to deferred revenue
Revenue recognized from deferred revenue
Balance as of end of year
Net loss attributable to common shareholders (numerator)
Basic weighted-average number of common shares outstanding (denominator)
Diluted weighted-average number of common shares outstanding (denominator)
Basic net loss per common share
Diluted net loss per common share
Antidilutive Security, Excluded EPS Calculation [Table]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total
Property, Plant and Equipment [Table]
Property, Plant and Equipment [Line Items]
Property plant and equipment estimated useful life
Warrants measurement input
Accounting Standards Update and Change in Accounting Principle [Table]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Series C-2 Preferred Stock $1,000.00 par value; 20,000 shares authorized; 10,719 and 8,576 issued and outstanding as of June 30, 2025 and December 31, 2024, respectively
Series C-2 Preferred Stock $1,000.00 par value; 20,000 shares authorized; 10,719 and 8,576 issued and outstanding as of June 30, 2025 and December 31, 2024, respectively
Accounts receivable, net of allowances of $61,773
Equity investments
Note receivable from HRCFG
LIABILITIES AND STOCKHOLDERS’ EQUITY
Warrant liability
Convertible notes payable – current portion, net
Interest Expense
Loss on debt extinguishment
Gain on settlement liability
Provision for income taxes
Net loss
Gain on changes in FV
Deferred tax liability
ScheduleOfRestatementAdjustmentsOfInterimCTable [Table]
Equity investments
Current lease liability
Long term lease liability
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Net income loss
Accumulated deficit
Redeem preferred stock
Net proceeds warrants
Proceeds from sale of common stock
Proceeds from Issuance or Sale of Equity
Proceeds from Issuance of Common Stock
Common Stock
NAYA Acquisition Pre-funded Warrants
Series C-1 Preferred
Series C-2 Preferred
Convertible Debenture
Business acquisition cost
Assets and liabilities acquired:
Cash
Other current assets
In process R&D
AP & accrued liabilities
Debt
Total assets and liabilities acquired
Loss on disposition
NTI Note Receivable
NTI Series A Preferred
Net assets
Cash
Prepaid expenses and other current assets
Intangible assets, net
Goodwill
Total assets held for sale
Accounts payable and accrued liabilities
Notes payable, net
Total liabilities held for sale
Revenue
Cost of revenue
Selling, general and administrative expenses
Research and development expenses
Impairment loss
Depreciation and amortization
Interest expense
Loss on discontinued operations
Converted shares to receive
Convertible debt
Converted shares to receive
Conversion of stock description
Convertible notes payable
Interest rate
Principal balance
Debt instrument maturity date
Redemption price
Common stock shares
Preferred stock shares
Common stock shares
Interest rate
InvestmentsInUnconsolidatedVariableInterestEntitiesOfFinancialStatementsTable [Table]
Percentage ownership
Investment in unconsolidated variable interest entities
Consolidation, Less-than-Wholly-Owned Subsidiary, Parent Ownership Interest, Effect of Change [Table]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Total earnings from unconsolidated VIEs
Operating revenue
Operating expenses
Current assets
Long-term assets
Current liabilities
Long-term liabilities
Net assets
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Variable interest entity commitment contribution
Variable interest entity units issued
Hurdle amount
Variable interest entity ownership, percentage
Investments
Notes receivable
Noncontrolling interest
Note receivable
Reduced in notes receivable
Principle balance
Equity method investments
Negative carrying value
SummaryOfTransactionWithVariableInterestEntitiesOfFinancialStatementsTable [Table]
INVOcell revenue
SummaryOfBalancesWithVariableInterestEntitiesOfFinancialStatementsTable [Table]
Accounts receivable
Notes payable
Raw materials
Finished goods
Total inventory
Estimated useful life
Property, plant and equipment, gross
Less: accumulated depreciation
Total equipment, net
Depreciation expense
Tradename
Noncompetition agreement
Less: accumulated amortization
Total intangible assets
Impairment Effects on Earnings Per Share [Table]
Impairment Effects on Earnings Per Share [Line Items]
Goodwill
Accumulated impairment losses
Goodwill, net
Impairment losses
Goodwill written off related to divesture
2026
2027
2028
2029
2030
Total
Intangible Asset, Finite-Lived [Table]
Finite-Lived Intangible Assets [Line Items]
Business combination, recognized asset acquired, identifiable intangible asset
Goodwill acquired
Intangible assets useful life
Impairment loss
Amortization of intangible assets
Goodwill impairment loss
Schedule Of Lease Components
Assets
ROU assets - operating lease
Total ROU assets
Liabilities
Current operating lease liability
Long-term operating lease liability
Total lease liabilities
Schedule Of Future Minimum Lease Payments
2026
2027
2028
2029
2030 and beyond
Total future minimum lease payments
Less: Interest
Total operating lease liabilities
Weighted average remaining lease term
Weighted average discount rate
Operating lease payments
Short-Term Debt [Table]
Short-Term Debt [Line Items]
Notes payable, gross
Less debt discount and financing costs
Total, net of discount
Less current portion
Long-term portion of notes payable
Demand notes financing fee percentage
Debt instrument, convertible, conversion price
Cumulative interest rate
Maturity date
2026
2027
2028
2029
2030 and beyond
Long term notes payable
Principal amount
Demand notes financing fee percentage
Proceeds from issuance of demand notes
Debt description
Loss of fair value of warrants
Payments to related party
Exercise price per share
Interest expense
Interest repaid
Balance debt
Accured interest
Proceeds from promissory notes
Interest on debenture
Receivables purchased value
Gross purchase price
Net cash proceeds
Principal amount
Debt discount
Loans payable
Interest rate description
Equity investment investment
Reimburse amount
Lender fees
Future sales purchase value
Warrants to purchase shares
Warrant exercise price
Number of shares issued
Purchase price of shares
Debt instrument, fee amount
Restricted shares issued
Interest for first twelve months
Debt maturity term
Principal amount
Number of shares issued
Outstanding interest paid
Debt instrument percentage
Conversion price
Proceeds from (Repayments of) Other Debt
Debt Instrument, Repaid, Principal
Principal amount
Principal amount
Extinguishment loss
Fair value conversion
Fair value
Gain on fair value
Additional paid in capital at current fair value
Shares to acquire
Shares to acquire value
Decrease in outstanding principal amount
Related Party Transaction [Table]
Related Party Transaction [Line Items]
Annual interest rate
Warrants purchase of common stock
Warrants exercises term
Interest costs incurred
Stock, Class of Stock [Table]
Class of Stock [Line Items]
Stockholders' Equity, Reverse Stock Split
Preferred stock stated value per share
Conversion price per share
Beneficially percentage
Preferred stock dividend percentage
Conversion price percentage
Debt conversion price percentage
Preferred stock aggregate stated value
Additional investment right exercised amount
Number of shares
Additional investments cash
Number of shares acquired
Aggregate stated value
Dividends
Dividends preferred stock issued
Dividends preferred stock accrued
Sale of stock
Share price
Debt description
Number of pre-funded warrants
Stock issued value
Purchase and acquire shares
Purchase and acquire shares, value
Number of pre-funded warrants
Proceeds from private placement
Number of warrants
Legal fees
Number of common stock upon cashless exercise
Common stock upon the exercise of cashless and prefunded warrants
Common stock share issued upon conversion
Common stock upon conversion debenture
Number of shares issued services
Number of shares, options outstanding
Weighted average exercise price, outstanding
Number of shares, options outstanding, granted
Weighted average exercise price, options outstanding, granted
Number of shares, options outstanding, exercised
Weighted average exercise price, options outstanding, exercised
Number of shares, options outstanding, expired
Weighted average exercise price, options outstanding, expired
Number of shares, options outstanding, canceled
Weighted average exercise price, outstanding, canceled
Number of shares, options outstanding
Weighted average exercise price, outstanding
Number of shares, options exercisable
Weighted average exercise price, options exercisable
Expected life of option-years
Expected stock price volatility
Expected dividend yield
Risk-free interest rate range
Total intrinsic value of options exercised
Total fair value of options vested
Accumulated Other Comprehensive Income (Loss) [Table]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Description
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period
Stock based compensation expense
Unrecognized stock based compensation
Weighted average remaining service period
Stock options, granted
Stock options, exercise price
Volatility rate
Call option value
Expected term
Estimated value
Fair value of servies rendered
Number of restricted stock shares
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of unit purchase options, granted
Weighted average exercise price, granted
Number of unit purchase options, exercised
Weighted average exercise price, exercised
Number of unit purchase options, canceled
Weighted average exercise price, canceled
Schedule Of Warrants Activity
Number of warrants, outstanding
Weighted average exercise price, outstanding
Number of warrants, issued
Weighted average exercise price, issued
Number of warrants, exercised
Weighted average exercise price, exercised
Number of warrants, expired
Weighted average exercise price, expired
Number of warrants, outstanding
Weighted average exercise price, outstanding
Class of Warrant or Right [Table]
Number of pre-funded warrant, issued
Number of pre-funded warrant, exercised
Number of pre-funded warrant, expired
UnitPurchaseOptionsAndWarrantsTable [Table]
Warrants exercise price
Warrant term
Fair value of warrants
Fair value remeasured
Change in fair value of warrants
Gross proceeds from warrant exercise
Warrant exercise price increase
Warrant exercise price decrease
Warrants at issuance
Net proceeds from warrants
Loss on issuance of warrants
Schedule of Segment Reporting Information, by Segment [Table]
Segment Reporting Information [Line Items]
Total revenue
Elimination of intersegment revenue
Total consolidated revenue
Cost of revenue
Sales and marketing
General and administrative
Research and development
Impairment loss
Segment profit (loss)
Other income (loss)
Other corporate expenses
Loss before taxes
Assets
Schedule of Revenue by Major Customers, by Reporting Segments [Table]
Revenue, Major Customer [Line Items]
Number of operating segments
Number of reportable segments
Concentartion risk percentage
Current
Deferred
Total federal income taxes
Current
Deferred
Total state income taxes
Current Federal
Current State
Total discontinued operations
Total income taxes
Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]
Pre-Tax Book Income at Statutory Rate
State Tax Expense (Benefit), net
Permanent Items
True-Ups
Change in Federal Valuation Allowance
True up of Basis in Intangible
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Pre-Tax Book Income at Statutory Rate, percentage
State Tax Expense, net, percentage
Permanent Items, percentage
True-Ups, percentage
Change in Federal Valuation Allowance, percentage
True up of Basis in Intangible, percentage
Total Expense (Benefit), percentage
Deferred tax assets:
Deferred Compensation
Stock Comp Expense - NQSO
Charitable Contribution
Goodwill and Intangibles
Right of Use Liability
Restricted Stock Unit
Investment in HRCFG
Investment in Bloom Partnership
Investment in NAYA Therapeutics
IRC Sec. 174 Capitalization
Federal NOL Carryforwards
State NOL DTA, net of Fed Ben
Deferred Revenue
Gross deferred tax assets
Deferred tax liabilities:
Fixed Assets
Goodwill and Intangibles
Investment in NAYA Therapeutics
Unrealized Gain/Loss on Fair Value
Right of Use Asset
Gross deferred tax liability
Less: valuation allowance
Net deferred tax liability
Effective Income Tax Rate Reconciliation [Table]
Effective Income Tax Rate Reconciliation [Line Items]
Deferred tax asset valuation allowance
Deferred income tax liabilities
Federal net operating loss carryforwards
Operating loss carryforwards expire
Operating loss carryforwards remaining balance
Restructuring Cost [Table]
Restructuring Cost and Reserve [Line Items]
Purchase consideration, value
Contractual obligation
Other commitment
Settlement obligation percentage
Gross funding proceeds
Gain on settlement
Subsequent Event [Table]
Subsequent Event [Line Items]
Gross proceeds
Purchase price
Number of shares issued on acquisition
Number of shares issued on acquisition, shares
Payments made in cash
Holdback funds
Reverse stock split
Notes, description
Extended maturity date
Monthly installments
Number of warrants to purchase common stock
Common stock exercise price
Warrants exercisable term
No insider trading flag.
Schedule of esimated useful lives of property and equiment [Table Text Block]
Manufacturing Equipment [Member]
Medical Equipment [Member]
Series C-2 Preferred Stock [Member]
Series C-1 Preferred Stock [Member]
Finite lived noncompetition agreement.
Wisconsin Fertility Institute Acquisition [Member]
NAYA Therapeutics [Member]
Assembled Workforce [Member]
2019 Stock Incentive Plan [Member]
Stock Incentive Plan [Member]
Cost of revenues.
Stock Options and Warrants Disclosure [Text Block]
Schedule of Unit Purchase Stock Options Activity [Table Text Block]
Gain loss on settlement agreement.
Unit Purchase Options [Member]
Gain loss on settlement of liability.
Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted average exercise price warrants.
Share based compensation arrangement by share based payment award non options grants weighted average exercise price.
Share based compensation arrangement by share based payment award non option equity instruments weighted average exercise price of warrants exercised.
Prefunded Warrant [Member]
Right of use assets.
Common stock warrants deemed dividends.
Inducement Letter Agreement [Member]
New Warrant [Member]
Existing Warrants [Member]
Stock issued during period value stock issued for cash.
Stock issued during period shares stock issued for cash.
Stock issued during period value preferred stock new issues.
Stock issued during period shares preferred stock new issues.
No Customers [Member]
Adjustments to additional paid in capital warrants issued for services.
Stock issued during period value warrant exercised.
Stock issued during period shares warrant exercised.
Fertility Clinic Services [Member]
INVOcell Device [Member]
Therapeutics [Member]
Intersegment revenues.
Other income loss.
Annual interest related party demand notes percentage.
Related Party Demand Notes [Member]
Related Party Convertible Notes [Member]
Convertible Note Payable One [Member]
Note Payable [Member]
Convertible Debenture Payable [Member]
Stock issued during period value warrants exercised cashless.
Stock issued during period shares warrants exercised cashless.
Notes Payable One [Member]
Stock issued during period value stock warrants exercised prefunded.
Stock issued during period shares stock warrants exercised prefunded.
Stock issued during period value reverse stock splits.
JAG Multi Investments LLC [Member]
Reclassification of temporary equity shares to permanent equity.
Income tax reconciliation true up.
Effective income tax rate reconciliation true up percent.
JAG Amendment [Member]
Deferred tax assets investment.
Deferred tax assets equity investments.
Deferred Tax Liabilites Valuation Allowance.
Stock issued during period shares dividends on preferred.
Stock issued during period value dividends on preferred.
Debt instrument financing fee percentage.
Second Installment [Member]
Receivables purchased value.
Sept 24 Cash Advance Agreement [Member]
Cedar [Member]
Revenue Loan and Security Agreement [Member]
Settlement obligation percentage.
Debt instrument reimburse amount.
Future sales purchased value.
Future Receipts Agreement [Member]
FirstFire Purchase Agreement [Member]
First Warrant [Member]
Second Warrant [Member]
Carter Terry and Company Inc [Member]
Interest expense debt for twelve months.
7% Secured Convertible Debenture [Member]
NAYA Therapeutics Inc [Member]
Stock issued during period shares C2 to common stock exchange shares.
Stock issued during period value C2 to common stock exchange shares.
August 2025 Amended and Restated Debenture [Member]
Convertible Debenture [Member]
May 2025 Amended And Restated Debenture [Member]
Non cash compensation for services.
Reserve on other assets.
Fair value of preferred stock issued for acquisition.
Common stock issued upon conversion notes payable and accrued interest.
Deemed dividend.
Common stock issued for accounts payable.
Preferred stock exchange.
Preferred stock redemption adjustment.
C-2 to common stock exchange.
Dividend on preferred stock.
Description of Business [Policy Text Block]
Accounting Pronouncements Not Yet Adopted [Policy Text Block]
Board of Directors [Member]
Series C-1 Convertible Preferred Stock [Member]
Series C-2 Convertible Preferred Stock [Member]
Debt instrument convertible threshold percentage of stock price.
Additional investment right exercised.
Number of common stock upon cashless exercise.
First Fire Warrant [Member]
Stock issued during period shares warrant exercised cashless and prefunded.
Legacy Naya Merger [Member]
Five Narrow Lane LP [Member]
Payments to acquire businesses common stock.
Payments to acquire businesses prefunded warrants.
Payments to acquire businesses series c one preferred stock.
Payments to acquire businesses series c two preferred stock
Payments to acquire businesses debenture.
Asset acquisition consideration notes receivable.
Payment to acquire business preferred stock amount.
Disposal group including discontinued operation goodwill.
Disposal group including discontinued operation research and development expenses.
Disposal group including discontinued operation impairment loss.
Variable interest entity commitment contribution.
Bloom INVO LLC [Member]
Bloom Agreement [Member]
Variable interest entity units issued.
Hurdle amount.
Georgia JV [Member]
Alabama JV [Member]
Schedule of Investments in Unconsolidated Variable Entities [Table Text Block]
HRCFG INVO, LLC [Member]
Investment in unconsolidated variable interest entities.
Schedule of Earnings from Investments in Unconsolidated Variable Interest Entities [Table Text Block]
Earning (Loss) from unconsolidated variable interest entities.
Schedule of Financial Information of Investment in Unconsolidated Variable Interest Entities [Table Text Block]
Agreement and Transaction with Variable Interest Entities [Text Block]
Summary of balances with variable interest entities [Table Text Block]
Clinic Revenue [Member]
Convertible Notes and Interest [Member]
Other [Member]
Revenue From External Customers [Member]
Inter Segment Revenue [Member]
Stock issued during period value preferred stock issued.
Stock issued during period shares preferred stock issued.
Stock issued during period value naya debt conversion.
Stock issued during period value consideration for legacy.
Stock issued during period shares consideration for legacy.
Other Debt [Member]
Preferred stock aggregate stated value.
AIR Exercise and Reload Agreement [Member]
Cash Advance Agreement [Member]
First Amended and Restated Debenture [Member]
Original Debenture [Member]
Second Amended and Restate Debenture [Member]
Securities Purchase Agreement [Member]
Pre-Funded Warrants [Member]
Common Warrants [Member]
December 2025 Private Placement [Member]
Unrecognized stock based compensation.
Share based compensation arrangement by share based payment award fair value assumptions call option value.
Estimated common stock options issued for services.
Share based compensation arrangements by share basedPayment award non options expired in period weighted average exercise price.
Consultants [Member]
Net Loss From Continuing Operations Per Common Share [Abstract]
Net Loss From Discontinued Operations Per Common Share [Abstract]
Stock issued during period value stock fair value of warrants with notes payable.
Revision of Previously Issued Consolidated Financial Statements [Policy Text Block]
Current federal tax expense benefit discontinued operations.
Current state and local tax expense benefit discontinued operations.
Income tax expense benefit discontinued operations.
Deferred tax assets right of use liability.
Deferred tax assets investment in naya therapeutics.
Deferred tax assets capitalization.
Deferred tax liabilities right of use asset.
Guarantee obligations non current carrying value.
Increase decrease in guarantee liability.
Permanent Items, percentage.
Permanent Items.
Liability for excess losses of equity method investee.
Alabama JV Note Receivable [Member]
Negative carrying value.
Goodwill written off related to divesture.
JAG August Letter [Member]
Lender fees.
Amended and Restated Debenture [Member]
Fair value remeasured.
Change in fair value of warrants.
December 2025 Warrants [Member]
Loss on issuance of warrants.
Adjustments to additional paid in capital changes in fair value of derivatives
Additions to accounts receivable.
Reductions to accounts receivable.
Conversion feature derivative.
Warrant liability.
Change in valuation of note receivable.
Change in valuation of warrant liability.
Change in valuation of conversion feature derivative.
Initial fair value of note receivable.
Initial fair value of warrant liability.
Assets, Current
Assets [Default Label]
Liabilities, Current
Liabilities [Default Label]
Equity, Attributable to Parent
Liabilities and Equity
Gain (Loss) on Disposition of Other Assets
Costs and Expenses
Operating Income (Loss)
Interest Expense, Nonoperating
Nonoperating Income (Expense)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest
Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
Preferred Stock Dividends and Other Adjustments
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share
Shares, Outstanding
Stock Redeemed or Called During Period, Shares
Temporary Equity, Including Noncontrolling Interest
Gain (Loss) on Disposition of Property Plant Equipment
Gain (Loss) from Litigation Settlement
Depreciation, Depletion and Amortization
Increase (Decrease) in Accounts Receivable
Increase (Decrease) in Inventories
Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Equity Securities, FV-NI
Increase (Decrease) in Employee Related Liabilities
Increase (Decrease) in Deferred Revenue
Increase (Decrease) in Other Current Liabilities
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Payments to Acquire Property, Plant, and Equipment
Payments for (Proceeds from) Businesses and Interest in Affiliates
Payments to Acquire Investments
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation
Payments for Repurchase of Trust Preferred Securities
Repayments of Notes Payable
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation
DividendOnPreferredStock
DeemedDividend
C2ToCommonStockExchange
Forgone Recovery, Individual Name
Outstanding Recovery, Individual Name
Awards Close in Time to MNPI Disclosures, Individual Name
Trading Arrangement, Individual Name
Partners' Capital
SharesOutstandingBeforeReclassification
TemporaryEquitySharesOutstandingBeforeReclassification
Members' Equity
ReclassificationsOfTemporaryToPermanentEquityOne
Inventory Disclosure [Text Block]
Lessee, Operating Leases [Text Block]
Consolidation, Variable Interest Entity, Policy [Policy Text Block]
Inventory, Policy [Policy Text Block]
Property, Plant and Equipment, Policy [Policy Text Block]
Income Tax, Policy [Policy Text Block]
Accounts Receivable, before Allowance for Credit Loss
Accounts Receivable, after Allowance for Credit Loss
Deferred Revenue, Revenue Recognized
InterestExpensesNonoperating
Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent
Business Combination, Recognized Asset Acquired, Cash and Cash Equivalent
Business Combination, Recognized Liability Assumed, Accounts Payable, Current
Business Combination, Recognized Liability Assumed, Long-Term Debt, Current
Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less)
Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents
Disposal Group, Including Discontinued Operation, Prepaid and Other Assets
Disposal Group, Including Discontinued Operation, Intangible Assets
DisposalGroupIncludingDiscontinuedOperationGoodwill
Disposal Group, Including Discontinued Operation, Accounts Payable and Accrued Liabilities
Disposal Group, Including Discontinued Operation, General and Administrative Expense
DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses
DisposalGroupIncludingDiscontinuedOperationImpairmentLoss
Disposal Group, Including Discontinued Operation, Depreciation and Amortization
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
Operating Costs and Expenses
Liabilities, Noncurrent
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Finite-Lived Intangible Assets, Accumulated Amortization
Intangible Assets, Net (Including Goodwill)
Goodwill, Gross
Goodwill, Impairment Loss, Net of Tax
Finite-Lived Intangible Assets, Net
Capitalized Contract Cost, Impairment Loss
RightOfUseAssets
Lessee, Operating Lease, Liability, to be Paid, Year One
Lessee, Operating Lease, Liability, to be Paid, Year Two
Lessee, Operating Lease, Liability, to be Paid, Year Three
Lessee, Operating Lease, Liability, to be Paid, Year Four
Lessee, Operating Lease, Liability, to be Paid
Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Long-Term Debt, Maturity, Year One
Long-Term Debt, Maturity, Year Two
Long-Term Debt, Maturity, Year Three
Long-Term Debt, Maturity, Year Four
Long-Term Debt, Maturity, after Year Five
Long-Term Debt
DebtInstrumentFinancingFeePercentage
Interest Expense, Operating and Nonoperating
Derivative Liability, Notional Amount
Derivative, Notional Amount
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Weighted average exercise price, beginning balance
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised
LossOnIssuanceOfWarrants
Cost of Revenue
Operating Lease, Impairment Loss
Other Expenses
Federal Income Tax Expense (Benefit), Continuing Operations
Current State and Local Tax Expense (Benefit)
Deferred State and Local Income Tax Expense (Benefit)
State and Local Income Tax Expense (Benefit), Continuing Operations
CurrentFederalTaxExpenseBenefitDiscontinuedOperations
CurrentStateAndLocalTaxExpenseBenefitDiscontinuedOperations
IncomeTaxExpenseBenefitDiscontinuedOperations
Effective Income Tax Rate Reconciliation, Percent
DeferredTaxAssetsInvestmentInNayaTherapeutics
Deferred Tax Assets, Other
Deferred Tax Assets, Gross
Deferred Tax Liabilities, Property, Plant and Equipment
Deferred Tax Liabilities, Goodwill and Intangible Assets
DeferredTaxLiabilitiesInvestment
DeferredTaxLiabilitiesUnrealizedGainlossOnFairValue
DeferredTaxLiabilitiesRightOfUseAsset
DeferredTaxLiabilitesValuationAllowance
Deferred Tax Assets, Net